Skip to content
20-F

Annual Report (Foreign)

COSCIENS Biopharma Inc. CSCIF

0001493152-26-012703

← back to feed
Filed
Mar 25, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 3.17M sh
Shares Diluted FY 2025 · Dec 31, 2024 2.58M sh
Shares Outstanding FY 2025 · Dec 31, 2025 3.18M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$8.47M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$14.57M
Cash And Equivalents FY 2025 · Dec 31, 2025 $7.31M
Cash And Equivalents FY 2025 · Dec 31, 2024 $16.39M
Current Liabilities FY 2025 · Dec 31, 2025 $3.61M
Current Liabilities FY 2025 · Dec 31, 2024 $7.22M
Total Liabilities FY 2025 · Dec 31, 2025 $17.59M
Total Liabilities FY 2025 · Dec 31, 2024 $21.91M
Current Assets FY 2025 · Dec 31, 2025 $11.5M
Current Assets FY 2025 · Dec 31, 2024 $23.98M
Total Assets FY 2025 · Dec 31, 2025 $21.43M
Total Assets FY 2025 · Dec 31, 2024 $35.07M
Eps Diluted FY 2025 · Dec 31, 2025 −$3.27
Eps Diluted FY 2025 · Dec 31, 2024 −$5.93
Eps Basic FY 2025 · Dec 31, 2025 −$3.27
Eps Basic FY 2025 · Dec 31, 2024 −$5.93
Sga Expense FY 2025 · Dec 31, 2025 $10.06M
Sga Expense FY 2025 · Dec 31, 2024 $10.45M
Sga Expense FY 2025 · Dec 31, 2023 $5.53M
Rd Expense FY 2025 · Dec 31, 2025 $2.95M
Rd Expense FY 2025 · Dec 31, 2024 $8.3M
Net Income FY 2025 · Dec 31, 2025 −$10.36M
Net Income FY 2025 · Dec 31, 2024 −$15.31M
Operating Income FY 2025 · Dec 31, 2025 −$10.68M
Operating Income FY 2025 · Dec 31, 2024 −$18.28M
Gross Profit FY 2025 · Dec 31, 2025 $2.65M
Gross Profit FY 2025 · Dec 31, 2024 $4.73M
Gross Profit FY 2025 · Dec 31, 2023 $2.94M
Cost Of Revenue FY 2025 · Dec 31, 2025 $4.85M
Cost Of Revenue FY 2025 · Dec 31, 2024 $4.86M
Revenue FY 2025 · Dec 31, 2025 $7.5M
Revenue FY 2025 · Dec 31, 2024 $9.59M